会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 65. 发明授权
    • Eye therapy system
    • 眼科治疗系统
    • US08398628B2
    • 2013-03-19
    • US12562625
    • 2009-09-18
    • David Muller
    • David Muller
    • A61B18/12
    • A61F9/013A61B18/1815A61B2018/00011A61F9/0079A61F9/009
    • The cornea is reshaped in multiple steps according to varying amounts of energy in varying patterns and/or at varying locations to achieve a customized reshaping of the cornea to address the specific needs of an individual patient. The varying amounts of energy may be applied via one or more conducting elements, which include an outer conductor and an inner conductor disposed within the outer conductor, a distal end of the outer conductor and the inner conductor defining the varying patterns. For example, one step may form a substantially circular lesion to flatten a first portion of the cornea to treat presbyopia, while another step may form a substantially circular and concentric lesion having a greater diameter to steepen a second portion of the cornea to treat hyperopia. Advantageously, continuous transitional regions are formed relative to the reshaped portions to provide vision for intermediate distances.
    • 根据不同模式和/或在不同位置处的不同量的能量,角膜重新成形,以实现角膜的定制重塑以满足个体患者的特定需要。 可以经由一个或多个导电元件施加不同量的能量,所述导电元件包括​​设置在外导体内的外导体和内导体,外导体的远端和限定变化图案的内导体。 例如,一个步骤可以形成基本圆形的损伤,以使角膜的第一部分平坦化以治疗老花眼,而另一步骤可以形成具有较大直径的基本圆形且同心的病变,以使角膜的第二部分陡峭以治疗远视。 有利地,相对于重新成形的部分形成连续的过渡区域以提供中间距离的视觉。
    • 67. 发明申请
    • SYSTEMS AND METHODS FOR RESHAPING AN EYE FEATURE
    • 用于修复眼睛特征的系统和方法
    • US20120303008A1
    • 2012-11-29
    • US13480127
    • 2012-05-24
    • David MullerVance Thompson
    • David MullerVance Thompson
    • A61F9/01A61F9/007
    • A61F9/013A61F9/00804A61F9/00836A61F2009/00853A61F2009/00872
    • Systems and methods include a cutting instrument that creates incisions in selected areas of the cornea; an eye therapy system that applies reshaping forces to the cornea; and a controller that determines the selected areas of the cornea for the incisions and the reshaping forces from the eye therapy system, such that the reshaping forces and the incisions combine to achieve corrective reshaping of the cornea. Other systems and methods include measuring an eye to determine a required amount of reshaping of a cornea; determining one or more doses of cross-linking agent and one or more corresponding doses of photoactivating light according to the required amount of reshaping; applying the cross-linking agent to the cornea; and delivering, from a light source, the photoactivating light to the area of the eye, the photoactivating light combining with the cross-linking agent to induce the corrective reshaping of the cornea.
    • 系统和方法包括在角膜的选定区域中产生切口的切割工具; 一种将矫正力应用于角膜的眼科治疗系统; 以及控制器,其确定角膜的选择区域用于切口和来自眼部治疗系统的重塑力,使得重塑力和切口结合以实现角膜的矫正重塑。 其他系统和方法包括测量眼睛以确定角膜重塑的所需量; 根据所需的重塑量确定一种或多种剂量的交联剂和一种或多种相应剂量的光活化光; 将交联剂施用于角膜; 以及从光源将光活化光输送到眼睛的区域,所述光活化光与交联剂结合以引起角膜的矫正重塑。
    • 68. 发明申请
    • STERILIZING APPLICATION OF CROSS-LINKING AGENT
    • 消毒交联剂的应用灭菌
    • US20120283621A1
    • 2012-11-08
    • US13468760
    • 2012-05-10
    • David Muller
    • David Muller
    • A61M37/00
    • A61F9/008A61B3/107A61F9/0079A61F2009/00844A61F2009/00857A61F2009/00872A61N5/062
    • A method for treating an eye includes applying, to an outer protective layer of an area of an eye, one or more initial doses of a cross-linking agent that acts as a photosensitizer. The method also includes delivering, from a light source, one or more initial doses of ultraviolet light to the area of the eye. The cross-linking agent increases absorption of the ultraviolet light by the area of the eye, and the absorption of the ultraviolet light sterilizes the area of the eye before the outer protective layer is penetrated. Additionally, the method includes penetrating the outer protective layer of the eye to provide access to an area below the outer protective layer. Moreover, the method includes applying a treatment to the eye via the access provided by cutting the outer protective layer. In some embodiments, the cross-linking agent is Riboflavin, and the treatment is LASIK surgery.
    • 用于治疗眼睛的方法包括将一种或多种初始剂量的用作光敏剂的交联剂施加到眼睛区域的外部保护层。 该方法还包括从光源将一个或多个初始剂量的紫外光输送到眼睛的区域。 交联剂通过眼睛的面积增加紫外线的吸收,并且紫外线的吸收在外部保护层被穿透之前对眼睛的区域进行消毒。 此外,该方法包括穿透眼睛的外保护层以提供对外保护层下方的区域的通路。 此外,该方法包括通过切割外部保护层提供的接近对眼睛进行治疗。 在一些实施方案中,交联剂是核黄素,治疗是LASIK手术。
    • 70. 发明授权
    • Determining site-to-site pacing delay for multi-site anti-tachycardia pacing
    • 确定多站点抗心动过速起搏的站点到站点起搏延迟
    • US08010194B2
    • 2011-08-30
    • US12416778
    • 2009-04-01
    • David Muller
    • David Muller
    • A61N1/00
    • A61N1/368A61B5/0452A61N1/3682A61N1/3684
    • An exemplary method includes delivering a pace using an electrode positioned on the lateral wall of the left ventricle of a heart, sensing the pace using an electrode positioned in the right ventricle of the heart, determining a left to right directional conduction time (TLR), delivering a pace using an electrode positioned in the right ventricle of the heart, sensing the pace using an electrode positioned on the lateral wall of the left ventricle of the heart, determining a right to left directional conduction time (TRL), calculating a site-to-site offset (VVATP) for multi-site anti-tachycardia pacing based on the left to right directional conduction time and the right to left directional conduction time and instructing an implantable device to deliver multi-site anti-tachycardia pacing using the site-to-site offset (VVATP). Other exemplary methods, devices, systems, etc., are also disclosed.
    • 一种示例性方法包括使用位于心脏左心室侧壁上的电极来传送步速,使用位于心脏右心室的电极来感测步速,确定从左到右的方向传导时间(TLR), 使用位于心脏右心室中的电极进行步调,使用位于心脏左心室侧壁上的电极感测步速,确定右向左方向传导时间(TRL),计算位置 - 基于从左到右定向导通时间和从右到左定向传导时间的多位点抗心动过速起搏的现场偏移(VVATP),并且指示植入装置使用位置偏移起搏来提供多部位抗心动过速起搏, 站点偏移(VVATP)。 还公开了其它示例性方法,装置,系统等。